EGFR V769_D770insASV

CI-VAR-00004624Explore in graph →NP_005219.2:p.Val769_Asp770insAlaSerValNM_005228.4:c.2300_2308dupCCAGCGTGGClinVar 177678 CIViC 736 rs727504263

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
EGFR V769_D770insASV	Erlotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1799 In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it… (full text at CIViC) PMID 26773740 · Klughammer et al., 2016 · Open in CIViC	civic
EGFR V769_D770insASV	Gefitinib	Predictive	C	Supports Resistance	2	submitted	EID4649 A 72 year old F never smoker with bronchioloalveolar carcinoma who had previously undergone surgery was tested for mutation in EGFR exons 18 to 21 and had Exon 20 in frame insertion. She was given fir… (full text at CIViC) PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
177678	drug response	no assertion criteria provided	0	Tyrosine kinase inhibitor response; Diffuse midline glioma, H3 K27M-mutant	somatic	2	Feb 24, 2010	clinvar

Lung Non-Small Cell Carcinoma1
EGFR V769_D770insASV	Erlotinib	Predictive	C	Supports Resistance	3	submitted	EID5943 A 60 year old female former smoker with 2 pack years and EGFR V769_D770insASV lung adenocarcinoma patient was given erlotinib as first line treatment, and had progressive disease as best response with… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic